CHRS vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Coherus Oncology, Inc.

(CHRS) is the cheapest at 1. 2x versus McKesson Corporation at 28. 9x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +308.

4%, compared to -87. 9% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: MCK returned +351. 9% versus CHRS's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at 0.

04β versus Coherus Oncology, Inc. 's 2. 29β — meaning CHRS is approximately 5219% more volatile than MCK relative to the S&P 500.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to 14. 9% for McKesson Corporation. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Coherus Oncology, Inc.

(CHRS) is the more profitable company, earning 398. 4% net margin versus 0. 9% for McKesson Corporation — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 2% versus -429. 5% for CHRS. At the gross margin level — before operating expenses — MCK leads at 3. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CHRS: 244.

0% to $6. 02.

In this comparison, MCK (0.

4% yield) pays a dividend. CHRS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

04), +351. 9% 10Y return). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +351. 9%, CHRS: -90. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CHRS is a small-cap deep-value stock; MCK is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.